Evidence map›Paper›PMID 42728348›Full record

ReviewNPJ precision oncology2026

A Boveri perspective on cancer biomarker testing using artificial intelligence.

Esther Conde, Susana Hernandez, Marta Alonso, Daniel Curto, Fernando Lopez-Rios

Abstract readReview
In one paragraph

Review in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Esther Conde *Department of Pathology, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Molecular and Computational Pathology Group, Research Institute Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain.
Susana Hernandez *Department of Pathology, Hospital Universitario 12 de Octubre. Molecular and Computational Pathology Group, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
Marta AlonsoDepartment of Pathology, Hospital Universitario 12 de Octubre. Molecular and Computational Pathology Group, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
Daniel CurtoDepartment of Pathology, Hospital Universitario 12 de Octubre. Molecular and Computational Pathology Group, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
Fernando Lopez-RiosDepartment of Pathology, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Molecular and Computational Pathology Group, Research Institute Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain. fernandolopezriosmoreno@gmail.com.

Funding

Fundacion Mutua Madrileña AP18051-2022Instituto de Salud Carlos III PI22-01700
6 · The paper itself

Abstract

Artificial intelligence (AI) can predict genomic alterations from histology, yet its adoption is slowed by a lack of trust. We argue that deliberate morphology (i.e., a cognitive understanding of histological features supported by standardized annotations) creates a bidirectional feedback loop between clinical practice and model outputs.We translate these observations into an actionable hypothesis for clinical and computational teams: that by enhancing explainability, deliberate morphology could facilitate the responsible deployment of AI biomarkers in oncology.

Identifiers

PMID42728348
PMCPMC13569831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.